Browsing Tag
SIX Swiss Exchange
9 posts
Swissquote (SIX: SQN) near 52-week low as crypto income falls 66%
Swissquote cut 2026 guidance after crypto income fell 66%. Can record client assets and non-crypto growth support an SQN recovery?
Samsung Biologics is not just buying PolyPeptide. It is buying into the GLP-1 supply chain
Samsung Biologics plans to acquire PolyPeptide for CHF 1.46 billion. Read how the deal targets peptide CDMO capacity and GLP-1 manufacturing demand.
Why ABB’s NASCAR microgrid showcase could matter beyond motorsports
Find out how ABB’s NASCAR Grid Control could shape ABBN stock sentiment, microgrid demand and temporary event power strategy today!
Inside Galderma’s €500m bond deal and what it reveals about the dermatology market’s financial momentum
Galderma raises €500M via a five-year eurobond to refinance IPO debt and strengthen its balance sheet. Discover what this means for GALD investors.
Galderma share buyback: CHF 232m repurchase follows full exit by EQT, ADIA, and Auba Investment
Galderma repurchases CHF 232M in shares as EQT exits. Discover what the buyback and ownership shift mean for the dermatology company and investors.
What Galderma Group AG’s new CFO appointment reveals about its next phase as a global dermatology company
Galderma Group AG appoints a new CFO as it enters its post-IPO phase. Find out what the leadership change signals for investors and strategy.
The fibrosis frontier: Can anti-fibrotic drugs finally deliver where weight-loss therapies fall short?
Can anti-fibrotic drugs succeed where weight-loss therapies have stalled? Explore the future of MASH treatment and why fibrosis is the key clinical frontier.
89bio stock soars 85% as Roche seals $3.5bn takeover—What’s behind the surge and what’s next?
Roche is buying 89bio for up to $3.5B to add Phase 3 MASH drug pegozafermin. Find out what the CVR means and how investors should read the deal today.
Novartis to acquire Regulus Therapeutics in $1.7bn deal to advance farabursen for ADPKD treatment
Novartis to acquire Regulus Therapeutics for $1.7 billion, gaining next-gen kidney drug farabursen for ADPKD. Read the market reaction and deal insights.